#{title}

Scandonest® 3% Plain Box of 50

Scandonest® 3% Plain Mepivacaine HCl 3% Injection, USP Local dental anesthesia by infiltration or nerve block in adults and pediatric patients. Formulation without vaso-constrictor for specific medical situations. Fast onset: 30 to 120 seconds in the maxilla and 1 to 4 minutes for the mandible. Duration: will ordinarily provide pupal anesthesia of about 20 minutes in the maxilla, and about 40 minutes in the mandible. No-methlylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml cartridges. Total of (50) cartridges. Reactions to Scandonest® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Scandonest® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Scandonest® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

Scandonest® 2% L and Levonordefrin 1:20,000 Box of 50

Scandonest® 2% L Mepivacaine HCl 2% and Levonordefrin 1:20,000 Injection, USP Local dental anesthethesia by infiltration or nerve block in adults and pediatric patients. Mepivacaine provides anesthesia for longer duration for more prolonged procedures: in the maxilla the duration is 1 to 2.5 hours and 2.5 to 5.5 hours in the mandible. No-methlyparaben formulation to avoid allergic reactions on sensitive patients. 100% percent latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Scandonest® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Scandonest® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Scandonest® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

Septocaine® Articaine HCl 4% and Epinephrine 1:100,000 Gold Box of 50

Local dental anesthesia in both simple and complex dental procedures. Septocaine and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Fast onset (1 to 9 minutes) to avoid delay before effective analgesia is achieved. Predictable duration of anesthesia: up to 60 minutes for infiltration injections and 120 minutes for nerve blocks. No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml cartridges. Total of (50) cartridges. Septocaine® is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Septocaine® and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Reactions to Septocaine® (pain and headache, for example, or convulsions or respiratory arrest following accidental intravascular injection) are characteristic of those associated with other amide-type local anesthetics. Septocaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Accidental intravascular injection may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners and/or clinicians who employ local anesthetic agents should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Septocaine®, along with other local anesthetics, is capable of producing methemoglobinemia. The clinical signs of methemoglobinemia are cyanosis of the nail beds and lips, fatigue and weakness. If methemoglobinemia does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended. Please see the Package Insert for prescribing information.

Mepivacaine HCI 3% Injection without Vasoconstrictor USP Box of 50

Mepivicaine 3% Hydrochloride Injection, USP Plain. Latex-free stoppers.

Septocaine® Articaine HCl 4% and Epinephrine 1:200,000 Silver Box of 50

Local dental anesthesia in both simple and complex dental procedures. For most routine dental procedures Septocaine 1:200,000 is preferred. Fast onset (1 to 9 minutes) to avoid delay before effective analgesia is achieved. Predictable duration of anesthesia: up to 60 minutes for infiltration injections and 120 minutes for nerve blocks. No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Includes: (5) Blisters of (10) 1.7ml cartridges. Total of (50) cartridges. Septocaine® is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Septocaine® and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Reactions to Septocaine® (pain and headache, for example, or convulsions or respiratory arrest following accidental intravascular injection) are characteristic of those associated with other amide-type local anesthetics. Septocaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Accidental intravascular injection may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners and/or clinicians who employ local anesthetic agents should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Septocaine®, along with other local anesthetics, is capable of producing methemoglobinemia. The clinical signs of methemoglobinemia are cyanosis of the nail beds and lips, fatigue and weakness. If methemoglobinemia does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended. Please see the Package Insert for prescribing information.

Vivacaine® Bupivacaine HCI 0.5% and Epinephrine 1:200,000 Injection Box of 50

Vivacaine® Bupivacaine HCl 0.5% and Epinephrine 1:200,000 Injection, USP Local dental anesthesia by infiltration or nerve block injections in adults. Anesthesia may last two to three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours. Onset of action is usually 2 to 10 minutes. No-methlyparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Vivacaine® are characteristic of those used with other amide-type local anesthetics. A major cause of reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Vivacaine® is contraindicated in patients with a known hypersensitivity to it or any local anesthetic agent of the amide type or to other components of Vivacaine® solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, an the personnel resources needed for proper management of toxic reactions and related emergencies. Vivacaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please seen the Package Insert for prescribing information.

Polocaine® 3% Mepivacaine Box of 50

Polocaine 3% Mepivicaine Hydrochloride Injection, USP Plain Provides anesthesia for both infiltration and nerve block techniques. Provides rapid onset duration for short term procedures in both upper and lower jaw. Known to not cause irritation and/or tissue damage. Plunger has easy smooth movement as both plunger and cartridge are silicon coated. Free from natural rubber latex leading to reduced allergic reactions. Sulfite Free thus reducing allergies for sensitive patients. The onset of action is rapid (30 to 120 seconds in the upper jaw; 1 to 4 minutes in the lower jaw) and 3% Polocaine will ordinarily provide operating anesthesia of 20 minutes in the upper jaw and 40 minutes in the lower jaw. Includes: (5) Blisters of (10) 1.7ml Glass Cartridges; Total of (50) cartridges. Polocaine is contraindicated in patients who are hypersensitive to local anesthetics. Polocaine should not be used in patients with congenital or idiopathic methemoglobinemia. Common precautions include aspiration prior to injection to help avoid intravascular injection.

Gold Articadent™ 4% 1:100000 Box of 50

Articaine HCI and Epinephrine Injection, USP 1:100,000

Silver Articadent™ 4% 1:200000 Box of 50

Articaine HCI and Epinephrine Injection, USP

Citanest® Plain 4% Prilocaine without Vasoconstrictor Box of 50

Citanest Plain 4% Prilocaine HCL without vasoconstrictor Provides anesthesia for both infiltration and nerve block techniques. Presents less toxicity in system tan other amide base local anesthetics. Exits the circulation faster than most of the other local anesthetics. Plunger has easy smooth movement as both plunger and cartridge are silicon coated. Free from natural rubber latex leading to reduced allergic reactions. The average time of onset and soft tissue duration is approximately less than 2 minutes and 2 hours respectively for infiltration injection with 4% Citanest Plain. This Injection provides pulpal anesthesia of approximately 10 minutes in maxillary infiltration injections. This has been found to provide complete anesthesia for procedures lasting an average of 20 minutes. When used for inferior alveolar nerve block, the time of onset 4% Citanest Plain Dental Injection averages less than three minutes with an average duration of soft tissue anesthesia of approximately 2.5 hours. Includes: (5) Blisters of (10) 1.8ml glass cartridges. Total of (50) cartridges. Citanest plain is contraindicated in patients who are hypersenstive to local anesthetics. Citanest plain should not be used in patients with congenital or idiopathic methemoglobinemia. Common precautions include aspiration prior to injection to help avoid intravascular injection.

Citanest® Forte 4% Prilocaine with Epinephrine 1:200,000 Box of 50

Citanest Forte 4% with Epinephrine 1:200,000 (prilocaine HCI and epinephrine injection, USP) Provides anesthesia for both infiltration and nerve block techniques. Presents less toxicity in system than other amide base local anesthetics. Exits the circulation faster than most other local anesthetics. Plunger has easy smooth movement as both plunger and cartridge are silicon coated. Free from natural rubber latex leading to reduced allergic reactions. Typical onset duration of Citanest Forte is around 2 minutes during infiltration with average soft tissue anesthesia of approximately 2.25 hours. In case of inferior alveolar nerve block the onset duration is less than 3 minutes while soft tissue anesthesia lasts for 3 hours. Includes: (5) Blisters of (10) 1.8ml glass cartridges. Total of (50) cartridges. Citanest Forte is contraindicated in patients who are hypersensitive to local anesthetics. Citanest Forte should not be used in patients with congenital or idiopathic methemoglobinemia. Common precautions include aspiration prior to injection to help avoid intravascular injection. Local anesthetic solutions like Citanest Forte that contain a vasoconstrictor should be used cautiously especially in patients with impared cardiovascular function or vascular disease.

Orabloc® Articaine Hydrochloride 4% and Epinephrine 1:100000 Injection Gold Box of 50

Articaine HCI and Epinephrine Injection, USP 1:100,000 • Aseptically manufactured • Rapid onset of anesthesia • Cartridge individually sealed • 24 month shelf life • Sodium edetate, latex and • methylparaben free

Orabloc® Articaine Hydrochloride 4% and Epinephrine 1:200000 Injection Silver Box of 50

Articaine HCI and Epinephrine Injection, USP 1:200,000 • Aseptically manufactured • Rapid onset of anesthesia • Cartridge individually sealed • 24 month shelf life • Sodium edetate, latex and • methylparaben free

Articaine Hydrochloride 4% and Epinephrine 1:100,000 Injection Latex-free Box of 50

Articaine Hydrochloride 4% and Epinephrine. Latex-free stoppers.

Articaine Hydrochloride 4% and Epinephrine 1:200,000 Injection Latex-free Box of 50

Graham Articaine Hydrochloride 4% and Epinephrine. Latex-free stoppers.

Carbocaine® 3% without Vasoconstrictor Box of 50

Carbocaine® 3% Mepivacaine and Levonordefrin Injection, USP without vasoconstrictor Local dental anesthesia by infiltration or nerve block in adults and pediatric patients. Formulation without vaso-constrictor for specific medical situations. Fast onset: 30 to 120 seconds in the maxilla and 1 to 4 minutes for the mandible. Duration: will ordinarily provide pulpal anesthesia of about 20 minutes in the maxilla.and about 40 minutes in the mandible. No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Carbocaine® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Carbocaine® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Carbocaine® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

Carbocaine® 2% with Neo-Cobefrin® Box of 50

Carbocaine® 2% with Neo-Cobefrin® Mepivacaine and Levonordefrin Injection, USP Local dental anesthesia by infiltration or nerve block in adults and pediatric patients. Mepivacaine provides anesthesia for longer duration for more prolonged procedures: in the maxilla the duration is 1 to 2.5 hours and 2.5 to 5.5 hours in the mandible. No-methlyparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Carbocaine® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Carbocaine® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Carbocaine® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

Marcaine® Bupivacaine HCl 0.5% and Epinephrine 1:200,000 Injection Box of 50

Marcaine® Bupivacaine HCl 0.5% and Epinephrine 1:200,000 Injection, USP No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Marcaine® are characteristic of those used with other amide-type local anesthetics. A major cause of reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Marcaine® is contraindicated in patients with a known hypersensitivity to it or any local anesthetic agent of the amide type or to other components of Marcaine® solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, an the personnel resources needed for proper management of toxic reactions and related emergencies. Marcaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please seen the Package Insert for prescribing information.